Premium
The use of remifentanil in the anaesthetic management of patients undergoing adrenalectomy: A report of three cases
Author(s) -
Breslin D. S.,
Farling P. A.,
Mirakhur R. K.
Publication year - 2003
Publication title -
anaesthesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.839
H-Index - 117
eISSN - 1365-2044
pISSN - 0003-2409
DOI - 10.1046/j.1365-2044.2003.03080.x
Subject(s) - medicine , remifentanil , pheochromocytoma , anesthesia , adrenalectomy , bradycardia , blood pressure , tachycardia , adverse effect , adrenergic , orthostatic vital signs , surgery , heart rate , receptor , propofol
Summary The use of remifentanil has been recommended because of its ability to minimise the hypertensive response to tracheal intubation and surgical stimulation in various types of surgery. We describe the use of remifentanil in the anaesthetic management of three cases of open adrenalectomy, two for removal of a phaeochromocytoma and one for removal of an adrenal cortical tumour. Although the use of remifentanil was associated with no adverse events in the patient undergoing resection of the adrenal cortical tumour, its administration was associated with significant hypotension and bradycardia in the two phaeochromocytoma patients, who had both been given α‐ and β‐adrenergic receptor blocking drugs before surgery. It did not prevent the increases in blood pressure or plasma catecholamine levels associated with tumour manipulation in these patients. Remifentanil should therefore be used with caution in patients receiving α‐ and β‐adrenergic receptor blocking drugs. The use of potent vasodilators may still be necessary during tumour manipulation even if remifentanil is being infused.